A Phase 4 interventional study of Placebo and Acetaminophen in Osteoporosis, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 45 Years to 79 Years. Per ClinicalTrials.gov, last updated 2011-02-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Osteoporosis by Novartis — none open to participants now, none under way, none of them phase 3. Osteoporosis · Novartis.
Among the 30 studies in Osteoporosis by Novartis, this one is the 6th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2007, is one of 4 in phase 4, and was the 21st registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →None of the 30 studies in Osteoporosis by Novartis is open now. The open studies under Osteoporosis, anywhere →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 45 Years to 79 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 793 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 190 across the 29 interventional studies, 1,551 across the 1 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Osteoporosis by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of acetaminophen or fluvastatin in reducing the rate of occurrence and the severity of post dose symptoms that may occur during the 3 day period following a zoledronic acid infusion in post menopausal women with low bone mass.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
Drug: Acetaminophen
2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
Drug: Fluvastatin
2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
Drug: Placebo
Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication.
Clinically significant increase in oral body temperature or used rescue medication ibuprofen \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.
Time frame: 0 - 3 days
Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature.
Clinically significant increase in oral body temperature \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.
Time frame: 0 - 3 days
Proportion of Patients Who Used Rescue Medication.
Patients that took rescue medication \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.
Time frame: 0 - 3 days
Number of Rescue Medication Tablets Taken
Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.
Time frame: 0 - 3 days
Time to First Rescue Medication After Infusion of Zoledronic Acid 5 mg.
Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.
Time frame: 0 - 3 days
Proportion of Patients With a Major Increase (Worsening) in Severity of Questionnaire Symptoms.
A major increase (worsening) in severity was defined as an increase in severity of 2 units or more from baseline at least once during the 3 days immediately following i.v. infusion of zoledronic acid 5 mg. The severity of the symptom was evaluated using a 4-point categorical scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).
Time frame: 0 - 3 days
Proportion of Patients Reporting Severe Questionnaire Symptoms.
A severe questionnaire symptom was defined as experiencing a severe specified symptom (feeling feverish, experiencing headaches, having aches and pains of muscles and joints) at least once post-baseline.
Time frame: 0 - 3 days
Change From Baseline in Visual Analog Scale (VAS) Measurement of Symptom Severity
Effect on severity of symptoms following i.v. infusion of zoledronic acid 5 mg. The VAS is a 100-mm linear visual analog scale (0 = no symptoms to 100 = severe symptoms). The baseline VAS measurement was defined as the VAS measurement recorded prior to the infusion.
Time frame: 0 - 3 days
| Milestone | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Started | 267 | 264 | 262 |
| Completed | 263 | 259 | 257 |
| Not completed | 4 | 5 | 5 |
| Withdrew: Adverse event | 3 | 3 | 4 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Administrative problems | 0 | 2 | 1 |
Clinically significant increase in oral body temperature or used rescue medication ibuprofen \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.
| proportion of patients | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Increase in oral body temperature:Yes | 0.607 | 0.398 | 0.618 |
| Increase in oral body temperature:No | 0.39 | 0.602 | 0.382 |
Clinically significant increase in oral body temperature \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.
| proportion of patients | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Increase in oral body temperature: Yes | 0.105 | 0.049 | 0.115 |
| Increase in oral body temperature: No | 0.891 | 0.951 | 0.885 |
Patients that took rescue medication \>= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.
| proportion of patients | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Took rescue medication >= 1 time: Yes | 0.573 | 0.386 | 0.595 |
| Took rescue medication >= 1 time: No | 0.423 | 0.614 | 0.405 |
Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.
| tablets | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Number of Rescue Medication Tablets Taken | 6.3 ± 4.41 | 5.7 ± 4.73 | 6.5 ± 4.78 |
Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.
| hours | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Time to First Rescue Medication After Infusion of Zoledronic Acid 5 mg. | 21.9 ± 12.21 | 28.2 ± 18.15 | 19.9 ± 40.95 |
A major increase (worsening) in severity was defined as an increase in severity of 2 units or more from baseline at least once during the 3 days immediately following i.v. infusion of zoledronic acid 5 mg. The severity of the symptom was evaluated using a 4-point categorical scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).
| proportion of patients | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Feeling feverish | 0.395 | 0.235 | 0.397 |
| Headache | 0.391 | 0.254 | 0.439 |
| Aches and pains of muscles/joints | 0.477 | 0.337 | 0.462 |
A severe questionnaire symptom was defined as experiencing a severe specified symptom (feeling feverish, experiencing headaches, having aches and pains of muscles and joints) at least once post-baseline.
| proportion of patients | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Feeling feverish | 0.135 | 0.076 | 0.145 |
| Headache | 0.157 | 0.068 | 0.160 |
| Aches and pains of muscles/joints | 0.303 | 0.212 | 0.302 |
Effect on severity of symptoms following i.v. infusion of zoledronic acid 5 mg. The VAS is a 100-mm linear visual analog scale (0 = no symptoms to 100 = severe symptoms). The baseline VAS measurement was defined as the VAS measurement recorded prior to the infusion.
| units on a scale | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Change from baseline to Day 1 - late evening | 7.6 ± 22.74 | 4.4 ± 18.00 | 6.0 ± 18.89 |
| Change from baseline to Day 2 - late evening | 18.9 ± 25.86 | 11.8 ± 23.22 | 20.8 ± 27.18 |
| Change from baseline to Day 3 - late evening | 6.2 ± 19.66 | 3.9 ± 17.59 | 6.6 ± 20.40 |
Collected over At the end of study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/267 (0.4%) | 34/267 (12.7%) |
| Acetaminophen | — | 2/264 (0.8%) | 39/264 (14.8%) |
| Fluvastatin | — | 2/262 (0.8%) | 36/262 (13.7%) |
| Event | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| UveitisEye disorders | 0/267 | 0/264 | 1/262 |
| PyrexiaGeneral disorders | 0/267 | 0/264 | 1/262 |
| ConvulsionNervous system disorders | 0/267 | 0/264 | 1/262 |
| SyncopeNervous system disorders | 0/267 | 1/264 | 0/262 |
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 0/267 | 1/264 | 0/262 |
| HypokalaemiaMetabolism and nutrition disorders | 1/267 | 0/264 | 0/262 |
| Event | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| NauseaGastrointestinal disorders | 7/267 | 16/264 | 8/262 |
| HeadacheNervous system disorders | 8/267 | 14/264 | 15/262 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/267 | 9/264 | 14/262 |
| MyalgiaMusculoskeletal and connective tissue disorders | 14/267 | 11/264 | 10/262 |
| Age, Customized(participants) | Placebo | Acetaminophen | Fluvastatin | Total |
|---|---|---|---|---|
| Between 45 and 55 years | 64 | 69 | 67 | 200 |
| Between 56 and 64 years | 102 | 98 | 92 | 292 |
| >=65 years | 101 | 97 | 103 | 301 |
| Sex/Gender, Customized(participants) | Placebo | Acetaminophen | Fluvastatin | Total |
|---|---|---|---|---|
| Female | 267 | 264 | 262 | 793 |
The record gives a start of Jun 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetaminophen · Fluvastatin